About Us - History of Endo Pharmaceuticals

1920 – A family-run pharmaceutical business is established in Manhattan, NY, later named Endo.

1969 – E.I. du Pont de Nemours and Company (DuPont) acquires Endo.

1990 – DuPont and Merck & Company form an independent joint venture, known as The DuPont Merck Pharmaceuticals Company (DuPont Merck).

1994 – DuPont Merck reestablishes Endo as a separate entity with the company. This entity is named Endo Laboratories L.L.C. and serves as DuPont Merck's generic division.

1997 – Three executives of DuPont Merck acquire certain products from DuPont Merck in a management buyout. With equity financing from Kelso & Company, a well-known, private investment firm, Carol A. Ammon, Chairman, President & CEO, and Mariann T. MacDonald, Executive Vice President, Operations, along with another colleague, purchase all of Endo Laboratories L.L.C.'s generic products along with 12 important brand products, including Percocet® and Percodan®. The principals name their new company Endo Pharmaceuticals Inc.

July 17, 2000 – Endo Pharmaceuticals acquires Algos Pharmaceutical Corporation, an innovative pharmaceutical company with a patent-protected technology, through a merger. As a result of this merger, Endo Pharmaceuticals begins to trade publicly (NASDAQ: ENDP).

October 2001 – Endo Pharmaceuticals successfully completes a secondary offering for a total of 12,925,000 shares of its common stock. The net proceeds were used to pay existing bank debt.